Among the worst vision-threatening conditions are age-related macular degeneration (AMD), the leading cause of blindness among people over age 55 in developed nations, and diabetic retinopathy (DR). In the United States alone, 13 million people have some stage of AMD and 45% of type 2 diabetics have a form of DR. Developing effective new treatments for AMD, DR, and myriad ocular diseases means researchers need both accurate safety and efficacy models, and experienced staff skilled in dosing procedures and end-point data collection ophthalmology services. At MPI Research, we provide the full spectrum of ocular expertise. Our team has extensive experience with ocular formulation preparation, ocular dosing routes, clinical ophthalmology examination techniques, specialty diagnostic procedures, tissue micro-dissection, PK/biodistribution, and ocular histopathology.
Sponsors return to us for experience, quality, precision, and teamwork needed to advance new ocular treatments and cures. MPI Research is ready to “open your eyes” to the ways we can meet your study needs in ophthalmology.